Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Summary

- VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader -

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Related coverage